Prostacyclin is important for normal lung function²

Decreased endogenous prostacyclin levels can lead to many of the pathologic changes that occur in PAH, including vasoconstriction, platelet aggregation, and smooth muscle cell proliferation.³

Although Guidelines recommend prostacyclin-class therapies as part of PAH management, prostacyclin may be underutilized as a therapeutic pathway, even among patients at higher risk.^4-7

Patients with PAH may have a prostacyclin deficiency in their lungs^2,3

Prostacyclin synthase expression in pulmonary arteries²*

In a retrospective analysis of patients with PAH, less than one-quarter received a prostacyclin-class therapy.^8†

*Prostacyclin synthase expression was evaluated in pulmonary artery tissue obtained from patients with PAH (n=12) and patients without PAH (n=7).²

^†A retrospective analysis of Truven Commercial and Medicare data from 2010-2015 involving 14,430 patients with documented evidence of PAH.⁸

Prostacyclin is important for normal lung function²

Patients with PAH may have a prostacyclin deficiency in their lungs^2,3

In a retrospective analysis of patients with PAH, less than one-quarter received a prostacyclin-class therapy.^8†

IMPORTANT SAFETY
INFORMATION

WARNINGS AND PRECAUTIONS

IMPORTANT SAFETY
INFORMATION

WARNINGS AND PRECAUTIONS

DRUG INTERACTIONS/SPECIFIC POPULATIONS

ADVERSE REACTIONS

Prostacyclin is important for normal lung function2

Patients with PAH may have a prostacyclin deficiency in their lungs2,3

In a retrospective analysis of patients with PAH, less than one-quarter received a prostacyclin-class therapy.8†

Prostacyclin is important for normal lung function²

Patients with PAH may have a prostacyclin deficiency in their lungs^2,3

In a retrospective analysis of patients with PAH, less than one-quarter received a prostacyclin-class therapy.^8†